Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.

Completed

• Conditions: COVID-19 Pandemic

• Registration Number: NCT05236309
• Lead Sponsor: Taipei City Hospital

Brief Summary

Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.

Main purpose:

Retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2.

Secondary purpose:

If there are related side effects after taking Chinese medicine.

Detailed Description

The large-scale coronavirus epidemic is a major global public health challenge in the 21st century. Since the 2003 Severe acute respiratory syndrome (SARS) epidemic spread globally and caused hundreds of deaths, the Middle East respiratory syndrome (Middle East respiratory syndrome, MERS) and coronavirus disease 2019(COVID-19) has caused a large-scale global spread and also caused a huge impact on the public health and medical system. In the country's current epidemic (Aug 1, 2021), more than 15,000 people have been diagnosed, and the number of deaths has exceeded 800. Among them, the Taipei epidemic is the most severe, and the Wanhua District of Taipei City is the hot zone. The investigators will discuss the changes in accumulation incidence rate(CIR) of the community and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.

This is a retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2 and discuss if there are related side effects after taking Chinese medicine.

Study Timeline

• Study Start: 2020-01-01
• Primary Completion: 2021-07-31
• Study Completion: 2021-11-18
• Study First Submitted: 2021-11-18
• Status Verified: 2022-02
• Study First Submitted QC: 2022-02-10
• Study First Posted: 2022-02-11
• Last Update Submitted: 2022-02-12
• Last Update Posted: 2022-03-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• From January 1, 2020 to July 31, 2021, Chinese medicine is used for patients with new coronary pneumonia epidemic prevention.

Exclusion Criteria

1. Patients who do not use traditional Chinese medicine for the prevention of new coronary pneumonia.
2. Patients who have signed and refused to provide medical records.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Investigation on the effect of using traditional Chinese medicine to prevent SARS-CoV-2 infection in two groups with cumulative incidence rate(CIR).	18 months	Compare the dangerous states within two groups with CIR.

Trial Locations

Locations (1)

Taipei City Hospital; 🇨🇳 Taipei, Taiwan